https://scholars.lib.ntu.edu.tw/handle/123456789/566403
標題: | Sustained immunogenicity of 2-dose human papillomavirus 16/18 AS04-adjuvanted vaccine schedules in girls aged 9-14 years: A randomized trial | 作者: | LI-MIN HUANG Puthanakit T. Cheng-Hsun C. Ren-Bin T. Schwarz T. Pellegrino A. Esposito S. Frenette L. McNeil S. Durando P. Rheault P. Giaquinto C. Horn M. Petry K.U. Peters K. Azhar T. Hillemanns P. De Simoni S. Friel D. Pemmaraju S. Hezareh M. Thomas F. Descamps D. Folschweiller N. Struyf F. |
關鍵字: | 2-dose schedule; Cervarix; Cervical cancer; Human papillomavirus (HPV) | 公開日期: | 2017 | 出版社: | Oxford University Press | 卷: | 215 | 期: | 11 | 起(迄)頁: | 1711-1719 | 來源出版物: | Journal of Infectious Diseases | 摘要: | Background. We previously reported the noninferiority 1 month after the last dose of 2-dose human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/18) vaccine schedules at months 0 and 6 (2D-M0, 6) and months 0 and 12 (2D-M0, 12) in girls aged 9-14 years compared with a 3-dose schedule at months 0, 1, and 6 (3D-M0, 1, 6) in women aged 15-25 years. Here, we report the results at study end (month 36 [M36]). Methods. Girls were randomized 1: 1 and received 2 vaccine doses either 6 months (2D-M0, 6) or 12 months apart (2D-M0, 12); women received 3 doses at months 0, 1, and 6 (3D-M0, 1, 6). Endpoints included noninferiority of HPV-16/18 antibodies for 2D- M0, 6 versus 3D-M0, 1, 6; 2D-M0, 12 versus 3D-M0, 1, 6; and 2D-M0, 12 versus 2D-M0, 6; and assessment of neutralizing antibodies, T cells, B cells, and safety. Results. At M36, the 2D-M0, 6 and 2D-M0, 12 schedules remained noninferior to the 3D-M0, 1, 6 schedule in terms of seroconversion rates and 3D/2D geometric mean titers for anti-HPV-16 and anti-HPV-18. All schedules elicited sustained immune responses up to M36. Conclusions. Both 2-dose schedules in young girls remained noninferior to the 3-dose schedule in women up to study conclusion at M36. The AS04-HPV-16/18 vaccine administered as a 2-dose schedule was immunogenic and well tolerated in young girls. ? The Author 2017. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85029152634&doi=10.1093%2finfdis%2fjix154&partnerID=40&md5=35fd27d4f49e650ba6ef2f677ed4822a https://scholars.lib.ntu.edu.tw/handle/123456789/566403 |
ISSN: | 0022-1899 | DOI: | 10.1093/infdis/jix154 | SDG/關鍵字: | neutralizing antibody; Wart virus vaccine; aluminum hydroxide; ASO4 mixture; human papillomavirus vaccine, L1 type 16, 18; lipid A; virus antibody; Wart virus vaccine; adolescent; antibody titer; Article; B lymphocyte; child; controlled study; dosage schedule comparison; drug dose regimen; drug safety; drug tolerability; drug withdrawal; female; human; Human papillomavirus type 16; Human papillomavirus type 18; immune response; immunogenicity; major clinical study; multicenter study; open study; papillomavirus infection; phase 3 clinical trial; priority journal; randomized controlled trial; seroconversion; systemic lupus erythematosus; T lymphocyte; vaccination; analogs and derivatives; blood; immunology; Adolescent; Aluminum Hydroxide; Antibodies, Viral; Child; Female; Human papillomavirus 16; Human papillomavirus 18; Humans; Lipid A; Papillomavirus Vaccines |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。